Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes Simplex Virus Type 2 Infection

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Aug 14

PMID 25117537

Citations 76

Authors

Piotr Orlowski

Emilia Tomaszewska

Marianna Gniadek

Piotr Baska

Julita Nowakowska

Justyna Sokolowska

Zuzanna Nowak

Mikolaj Donten

Grzegorz Celichowski

Jaroslaw Grobelny

Malgorzata Krzyzowska

Affiliations

Soon will be listed here.

Abstract

The interaction between silver nanoparticles and herpesviruses is attracting great interest due to their antiviral activity and possibility to use as microbicides for oral and anogenital herpes. In this work, we demonstrate that tannic acid modified silver nanoparticles sized 13 nm, 33 nm and 46 nm are capable of reducing HSV-2 infectivity both in vitro and in vivo. The antiviral activity of tannic acid modified silver nanoparticles was size-related, required direct interaction and blocked virus attachment, penetration and further spread. All tested tannic acid modified silver nanoparticles reduced both infection and inflammatory reaction in the mouse model of HSV-2 infection when used at infection or for a post-infection treatment. Smaller-sized nanoparticles induced production of cytokines and chemokines important for anti-viral response. The corresponding control buffers with tannic acid showed inferior antiviral effects in vitro and were ineffective in blocking in vivo infection. Our results show that tannic acid modified silver nanoparticles are good candidates for microbicides used in treatment of herpesvirus infections.

Citing Articles

The Influence of the AgNPs Ligand on the Antiviral Activity Against HSV-2.

Tomaszewska E, Bednarczyk K, Janicka M, Chodkowski M, Krzyzowska M, Celichowski G Int J Nanomedicine. 2025; 20:2659-2671.

PMID: 40061878 PMC: 11890083. DOI: 10.2147/IJN.S496050.

Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy.

Loo Y, Yusoh N, Lim W, Ng C, Zahid N, Azmi I Nanomedicine (Lond). 2025; 20(4):401-416.

PMID: 39848784 PMC: 11812329. DOI: 10.1080/17435889.2025.2452151.

Advances in Metal and Metal Oxide Nanomaterials for Topical Antimicrobial Applications: Insights and Future Perspectives.

Medic B, Tomic N, Lagopati N, Gazouli M, Pojskic L Molecules. 2024; 29(23.

PMID: 39683711 PMC: 11643765. DOI: 10.3390/molecules29235551.

Silver Nanoparticles in Therapeutics and Beyond: A Review of Mechanism Insights and Applications.

Eker F, Duman H, Akdasci E, Witkowska A, Bechelany M, Karav S Nanomaterials (Basel). 2024; 14(20).

PMID: 39452955 PMC: 11510578. DOI: 10.3390/nano14201618.

Fas/FasL-Mediated Apoptosis and Inflammation Contribute to Recovery from HSV-2-Mediated Spinal Cord Infection.

Krzyzowska M, Patrycy M, Chodkowski M, Janicka M, Kowalczyk A, Skulska K Viruses. 2024; 16(9).

PMID: 39339840 PMC: 11436029. DOI: 10.3390/v16091363.

References

Morones J, Elechiguerra J, Camacho A, Holt K, Kouri J, Tapia Ramirez J . The bactericidal effect of silver nanoparticles. Nanotechnology. 2010; 16(10):2346-53. DOI: 10.1088/0957-4484/16/10/059. View

Liu W, Wu Y, Wang C, Li H, Wang T, Liao C . Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicology. 2010; 4(3):319-30. DOI: 10.3109/17435390.2010.483745. View

Akhtar J, Shukla D . Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J. 2009; 276(24):7228-36. PMC: 2801626. DOI: 10.1111/j.1742-4658.2009.07402.x. View

Lin L, Chen T, Chung C, Noyce R, Grindley T, McCormick C . Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol. 2011; 85(9):4386-98. PMC: 3126266. DOI: 10.1128/JVI.01492-10. View

Piret J, Boivin G . Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2010; 55(2):459-72. PMC: 3028810. DOI: 10.1128/AAC.00615-10. View

Milligan G . Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J Virol. 1999; 73(8):6380-6. PMC: 112717. DOI: 10.1128/JVI.73.8.6380-6386.1999. View

Gupta R, Warren T, Wald A . Genital herpes. Lancet. 2007; 370(9605):2127-37. DOI: 10.1016/S0140-6736(07)61908-4. View

Xiang D, Zheng Y, Duan W, Li X, Yin J, Shigdar S . Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. Int J Nanomedicine. 2013; 8:4103-13. PMC: 3817021. DOI: 10.2147/IJN.S53622. View

Haslam E . Vegetable tannins - lessons of a phytochemical lifetime. Phytochemistry. 2007; 68(22-24):2713-21. DOI: 10.1016/j.phytochem.2007.09.009. View

10.

Campbell S, Perry V, Pitossi F, Butchart A, Chertoff M, Waters S . Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver. Am J Pathol. 2005; 166(5):1487-97. PMC: 1606402. DOI: 10.1016/S0002-9440(10)62365-6. View

11.

Tobian A, Quinn T . Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS. 2009; 4(4):294-9. PMC: 2752434. DOI: 10.1097/COH.0b013e32832c1881. View

12.

Iijima N, Mattei L, Iwasaki A . Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A. 2010; 108(1):284-9. PMC: 3017177. DOI: 10.1073/pnas.1005201108. View

13.

Pal S, Tak Y, Song J . Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol. 2007; 73(6):1712-20. PMC: 1828795. DOI: 10.1128/AEM.02218-06. View

14.

Johnston H, Hutchison G, Christensen F, Peters S, Hankin S, Stone V . A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol. 2010; 40(4):328-46. DOI: 10.3109/10408440903453074. View

15.

Orlowski P, Krzyzowska M, Zdanowski R, Winnicka A, Nowakowska J, Stankiewicz W . Assessment of in vitro cellular responses of monocytes and keratinocytes to tannic acid modified silver nanoparticles. Toxicol In Vitro. 2013; 27(6):1798-808. DOI: 10.1016/j.tiv.2013.05.010. View

16.

Kim J, Kuk E, Yu K, Kim J, Park S, Lee H . Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007; 3(1):95-101. DOI: 10.1016/j.nano.2006.12.001. View

17.

De Lima R, Seabra A, Duran N . Silver nanoparticles: a brief review of cytotoxicity and genotoxicity of chemically and biogenically synthesized nanoparticles. J Appl Toxicol. 2012; 32(11):867-79. DOI: 10.1002/jat.2780. View

18.

Namvar L, Olofsson S, Bergstrom T, Lindh M . Detection and typing of Herpes Simplex virus (HSV) in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous for HSV types 1 and 2. J Clin Microbiol. 2005; 43(5):2058-64. PMC: 1153722. DOI: 10.1128/JCM.43.5.2058-2064.2005. View

19.

Khan N, Ahmad A, Hadi S . Anti-oxidant, pro-oxidant properties of tannic acid and its binding to DNA. Chem Biol Interact. 2000; 125(3):177-89. DOI: 10.1016/s0009-2797(00)00143-5. View

20.

Yilma A, Singh S, Dixit S, Dennis V . Anti-inflammatory effects of silver-polyvinyl pyrrolidone (Ag-PVP) nanoparticles in mouse macrophages infected with live Chlamydia trachomatis. Int J Nanomedicine. 2013; 8:2421-32. PMC: 3709643. DOI: 10.2147/IJN.S44090. View